Key result
Short-term infusion of Angiotensin II increased blood pressure to 146/97 mmHg but had no effect on PAI-1 activities or plasma concentrations in healthy volunteers.
Why the study?
Does short-term infusion of Angiotensin II affect PAI-1 activities and plasma concentrations in healthy subjects?
Does short-term infusion of Angiotensin II affect PAI-1 activities and plasma concentrations in healthy subjects?
Short-term infusion of Angiotensin II does not acutely alter PAI-1 levels in healthy subjects, suggesting no immediate direct effect on fibrinolytic balance despite significant hemodynamic responses.
Answers are grounded in this paper and cite their sources.
Short-term Ang II infusion does not alter PAI-1 in healthy volunteers; leaves open chronic exposure or disease-state effects on fibrinolysis.
OBJECTIVE: Numerous studies have provided evidence for a direct functional link between the renin-angiotensin-aldosterone system and the fibrinolytic system. Angiotensin II has been suggested to mediate this interrelationship because this peptide was shown to stimulate plasminogen activator inhibitor-1 (PAI-1) in experimental settings. However, evidence from studies in man regarding effects of Angiotensin II on fibrinolytic function remains controversial. METHODS: In the present study, we have therefore infused Angiotensin II at doses of 1, 3 and 10 ng kg(-1) min(-1), each over 45 min, in 9 healthy volunteer subjects without and with pretreatment with a single dose of the Angiotensin II (type 1) (AT1)-receptor antagonist valsartan (160 mg). RESULTS: Angiotensin II infusion dose-dependently increased plasma Angiotensin II concentrations and systolic/diastolic arterial blood pressure from 121 +/- 2/70 +/- 2 mmHg to 146 +/- 2/97 +/- 1 mmHg (p < 0.001). The maximum increase in blood pressure was completely abolished (118 +/- 3/72 +/- 1 mmHg) when Angiotensin II was infused in volunteers pretreated with valsartan. In spite of the marked hemodynamic changes seen with the Angiotensin II infusion, no effect could be demonstrated on the activity and antigen concentration of PAI-1. Furthermore, pretreatment of the volunteers with valsartan markedly blunted the increase in arterial blood pressure but was not associated with changes in PAI-1. CONCLUSION: In conclusion, in healthy volunteer subjects, short-term infusion of Angiotensin II without and with concomitant administration of an AT1-receptor antagonist has no effect on PAI-1 activities and plasma concentrations.
No takes yet. Share an insight, caveat, or question.
Lottermoser et al. (2004) studied Healthy volunteers (n=9). Angiotensin II with or without valsartan vs. Without valsartan pretreatment was evaluated on Activity and antigen concentration of PAI-1. Short-term infusion of Angiotensin II increased blood pressure to 146/97 mmHg but had no effect on PAI-1 activities or plasma concentrations in healthy volunteers.
Synapse has enriched 10 related papers. Consider them for comparative context: